Also found in: Medical, Wikipedia.
CDK9Cyclin Dependent Kinase 9
References in periodicals archive ?
With the development of atuveciclib, we have shown that this principle can by all means be used in drugs provided the CDK9 inhibitor is specific enough, explains Bert Klebel, co-director of LDC with Peter Nussbaumer.
CDK9 is a protein of potential clinical significance in oncology because of its role in promoting genomic integrity in response to agents that induce replication stress and DNA damage.
Intensive research in the cancer field has unraveled the role of BET proteins in NF-[kappa]B pathway regulation, demonstrating that BRD4 binding to acetylated lysine-310 of RelA is essential for recruiting BRD4 and CDK9 to the promoters of specific NF-[kappa]B target genes [90-93].
En un estudio con un modelo nuevo de [T.sub.Res] tambien se observaron bajos niveles de ARN polimerasa II en el 5' LTR proviral junto con altos niveles de HDACl, ademas de bajos niveles nucleares de CycT1 y de CDK9 (33).
"If we can interrupt the activity of Brd4 or Cdk9, we may be able to prevent latent infection from becoming active," said Finkel.
Data will also be presented on MCL1/CDK9 targeting by AZD5991 and the CDK9 inhibitor AZD4573 (Abstract #768).
Demonstrated 13,000- to 49,000-fold greater selectivity for CDK7 over other CDK family members, including CDK2, CDK9 and CDK12.
The company added TP-1287 is an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor entering into a Phase 1 study in patients with advanced solid tumours (NCT03604783).
Our preliminary work revealed that an inhibitor targeting cyclin-dependent kinase 9 (cdk9) strikingly synergized with targeting egfr receptor family signaling to inhibit cell proliferation of tnbc cell lines.
Alvocidib is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) that controls the expression of a survival factor MCL-1, while Venetoclax is a small molecule inhibitor of B-cell lymphoma-2 (BCL-2).
Study TPI-ALV-201 is examining the efficiency of alvocidib, an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), in combination with the authorized agents cytarabine and mitoxantrone in relapsed/refractory AML patients whose leukemia depends on MCL-1.
The product is a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), which controls the expression of a survival factor, MCL-1.